Astec LifeSciences Limited
Astec LifeSciences has set record dates for the redemption of two Commercial Papers. These CPs, totaling Rs. 50 crore, are maturing in May 2026, indicating timely debt servicing.
Apr 29 2026 18:04:00
Astec LifeSciences Limited
Astec LifeSciences reported Q4 FY26 consolidated revenue of ₹158.62 crore, a 32.79% YoY increase, with net loss reducing to ₹7.75 crore. The full FY26 consolidated revenue rose 17.53% to ₹448.15 crore, significantly narrowing its net loss to ₹80.88 crore.
Apr 27 2026 20:04:00
Astec LifeSciences Limited
Astec LifeSciences reported Q4 FY26 consolidated revenue of ₹158.62 crore, a 32.79% YoY increase, with net loss reducing to ₹7.75 crore. The full FY26 consolidated revenue rose 17.53% to ₹448.15 crore, significantly narrowing its net loss to ₹80.88 crore.
Apr 27 2026 20:04:00
Astec LifeSciences Limited
Astec LifeSciences reported Q4 FY26 consolidated revenue of ₹158.62 crore, a 32.79% YoY increase, with net loss reducing to ₹7.75 crore. The full FY26 consolidated revenue rose 17.53% to ₹448.15 crore, significantly narrowing its net loss to ₹80.88 crore.
Apr 27 2026 20:04:00
Astec LifeSciences Limited
Astec LifeSciences confirmed that security cover is not applicable for its 8.90% unsecured Non-Convertible Debentures. This compliance update pertains to NCDs worth ₹49 crore for the quarter ended March 31, 2026, aligning with SEBI guidelines.
Apr 27 2026 20:04:00
Astec LifeSciences Limited
Astec LifeSciences confirmed that security cover is not applicable for its 8.90% unsecured Non-Convertible Debentures. This compliance update pertains to NCDs worth ₹49 crore for the quarter ended March 31, 2026, aligning with SEBI guidelines.
Apr 27 2026 20:04:00
Astec LifeSciences Limited
Astec LifeSciences reported no deviation in the utilization of funds from its ₹49 crore listed non-convertible debentures for Q4 FY26. The entire amount, raised via private placement on March 28, 2025, was utilized for general corporate purposes.
Apr 27 2026 20:04:00
Astec LifeSciences Limited
Astec LifeSciences reported strong Q4 FY26 financial results, with total income rising 34% to ₹161.3 crore and EBITDA increasing 87% to ₹11.8 crore. The full year FY26 loss significantly reduced to ₹80.9 crore from ₹134.7 crore.
Apr 27 2026 20:04:00
Astec LifeSciences Limited
Astec LifeSciences reported Q4 FY26 consolidated revenue of ₹158.62 crore, a 32.79% YoY increase, with net loss reducing to ₹7.75 crore. The full FY26 consolidated revenue rose 17.53% to ₹448.15 crore, significantly narrowing its net loss to ₹80.88 crore.
Apr 27 2026 19:04:00
Astec LifeSciences Limited
Astec LifeSciences reported Q4 FY26 consolidated revenue of ₹158.62 crore, a 32.79% YoY increase, with net loss reducing to ₹7.75 crore. The full FY26 consolidated revenue rose 17.53% to ₹448.15 crore, significantly narrowing its net loss to ₹80.88 crore.
Apr 27 2026 19:04:00
Read More